Literature DB >> 22836646

Immune response to influenza vaccine in hemodialysis patients with chronic renal failure.

Agnieszka Mastalerz-Migas1, Andrzej Steciwko, Lidia B Brydak.   

Abstract

Chronic renal failure and dialysis belong to contraindications to vaccination with live vaccines. The objective of this study was to evaluate the humoral response to influenza vaccination consisting of the formation of antibodies against hemagglutinin and neuraminidase in patients undergoing chronic hemodialysis due to chronic renal failure. The study included 173 patients treated at a dialysis station in the Silesian region in Poland. The patients were assigned to the following groups: Group A-71 hemodialysis patients, mean age 65.4 ± 14.5 years; mean time of dialysis therapy 38.9 ± 31.7 months, vaccinated against influenza; Group B-39 hemodialysis patients, mean age 64 ± 13.5 years; mean time of dialysis therapy 45.0 ± 45.2 months, not vaccinated against influenza; and Group C-63 healthy patients, mean age 44.1 ± 21.2 years, vaccinated against influenza - control group. The vaccinated patients (Groups A & C) received a single dose of Agrippal influenza vaccine (Novartis) containing hemagglutinin from three strains of the influenza virus: A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2), and B/Brisbane/60/2008. The serological response to vaccination was assessed from antihemagglutinin (anti-HA) and antineuraminidase antibody assays (anti-NA). We found that the protection level of antibodies (protection rate) against H1 was only 40% among the vaccinated hemodialysis patients, as opposed to 65% in controls. The level of anti-H3 antibodies was similar in both groups of vaccines; 68% in dialysis patients and 75% in controls. The level of anti-HB antibodies was higher in the dialysis patient than in controls; 70% vs. 38%, respectively. The response rate to H1 antigen a month after vaccination was almost twice lower in the hemodialysis patients than in healthy controls vaccinated against influenza; 37% vs. 65%, respectively. We conclude that there is a rather insufficient serological response in the group of hemodialysis patients vaccinated with a single dose of influenza vaccine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22836646     DOI: 10.1007/978-94-007-4549-0_35

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  15 in total

1.  Infections Requiring Hospitalization in Patients on Hemodialysis.

Authors:  David T Gilbertson; James B Wetmore
Journal:  Clin J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 8.237

2.  Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population.

Authors:  David T Gilbertson; Kenneth J Rothman; Glenn M Chertow; Brian D Bradbury; M Alan Brookhart; Jiannong Liu; Wolfgang C Winkelmayer; Til Stürmer; Keri L Monda; Charles A Herzog; Akhtar Ashfaq; Allan J Collins; James B Wetmore
Journal:  J Am Soc Nephrol       Date:  2019-01-24       Impact factor: 10.121

3.  Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease.

Authors:  J Bradley Layton; Leah J McGrath; John M Sahrmann; Yinjiao Ma; Vikas R Dharnidharka; Caroline O'Neil; David J Weber; Anne M Butler
Journal:  Vaccine       Date:  2020-06-19       Impact factor: 3.641

4.  ChAdOx1 nCoV-19 Immunogenicity and Immunological Response Following COVID-19 Infection in Patients Receiving Maintenance Hemodialysis.

Authors:  Wisit Prasithsirikul; Tanawin Nopsopon; Phanupong Phutrakool; Pawita Suwanwattana; Piyawat Kantagowit; Wannarat Pongpirul; Anan Jongkaewwattana; Krit Pongpirul
Journal:  Vaccines (Basel)       Date:  2022-06-16

5.  SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan.

Authors:  Daisuke Kanai; Hiromichi Wakui; Tatsuya Haze; Kengo Azushima; Sho Kinguchi; Shunichiro Tsukamoto; Tomohiko Kanaoka; Shingo Urate; Yoshiyuki Toya; Nobuhito Hirawa; Hideaki Kato; Fumimasa Watanabe; Kanako Hanaoka; Masaaki Hanaoka; Hiroshi Mitsuhashi; Satoshi Yamaguchi; Toshimasa Ohnishi; Kouichi Tamura
Journal:  Clin Exp Nephrol       Date:  2022-06-25       Impact factor: 2.617

6.  High-Dose Seasonal Influenza Vaccine in Patients Undergoing Dialysis.

Authors:  Dana C Miskulin; Daniel E Weiner; Hocine Tighiouart; Eduardo K Lacson; Klemens B Meyer; Taimur Dad; Harold J Manley
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-23       Impact factor: 8.237

7.  Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season.

Authors:  Anna M Jagielska; Lidia B Brydak; Aneta S Nitsch-Osuch
Journal:  Med Sci Monit       Date:  2021-05-17

Review 8.  Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety.

Authors:  Cornelius Remschmidt; Ole Wichmann; Thomas Harder
Journal:  BMC Med       Date:  2014-12-19       Impact factor: 8.775

9.  Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.

Authors:  Eva Schrezenmeier; Leon Bergfeld; David Hillus; Joerg-Detlev Lippert; Ulrike Weber; Pinkus Tober-Lau; Irmgard Landgraf; Tatjana Schwarz; Kai Kappert; Ana-Luisa Stefanski; Arne Sattler; Katja Kotsch; Thomas Dörner; Leif Erik Sander; Klemens Budde; Fabian Halleck; Florian Kurth; Victor Max Corman; Mira Choi
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

Review 10.  Effectiveness of influenza vaccine in patients on hemodialysis--a review.

Authors:  Agnieszka Mastalerz-Migas; Elżbieta Gwiazda; Lidia B Brydak
Journal:  Med Sci Monit       Date:  2013-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.